The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
Observational Model: Cohort, Time Perspective: Cross-Sectional
To determine whether the drug, Bevacizumab (a monoclonal anti VEGF-A antibody), which is approved to treat patients with metastatic colon cancer induces hyperprolactinemia (increased prolactin secretion) in humans with intact pituitary function.
Patients will have their blood drawn before their first Bevacizumab infusion and then again 6 weeks later.
Shlomo Melmed, MD
Cedars-Sinai Medical Center
United States: Institutional Review Board
|Cedars-Sinai Medical Center||Los Angeles, California 90048|